Coppé and colleagues define a resistance mechanism to combination BRAF- and EGFR-targeted therapy in BRAFV600E colorectal cancers that could be overcome in vitro and in vivo by repurposing COX2 inhibitors.
- Ana Ruiz-Saenz
- Chloe E. Atreya
- Jean-Philippe Coppé